F-1/A: PomDoctor Limited Files for Nasdaq IPO Amidst Going Concern Doubts and VIE Structure Risks

PomDoctor Limited, a Cayman Islands holding company operating a leading online medical services platform for chronic diseases in China, is seeking to raise up to $24.9 million in an initial public offering on Nasdaq, despite its auditor expressing substantial doubt about its ability to continue as a going concern.

Summary

• PomDoctor Limited is a Cayman Islands holding company primarily operating in China through its subsidiaries and contractual arrangements with its Variable Interest Entity (VIE), Guangzhou Qilekang Digital Health Medical Technology Co., Ltd.
• The company is a leading online medical services platform for chronic diseases in China, ranking sixth in China's Internet hospital market by contracted doctors in 2022.
• As of December 31, 2024, the company had over 214,217 contracted doctors and 699,338 transacting patients, with approximately 3.13 million prescriptions issued.
• Net revenues increased by 12.4% from RMB304.9 million in 2023 to RMB342.6 million (US$46.9 million) in 2024.
• The company incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• Operating cash flow improved from negative RMB45.8 million in 2023 to negative RMB16.1 million (US$2.2 million) in 2024.
• The company had a working capital deficit of RMB141.6 million (US$19.4 million) and an accumulated deficit of RMB2,263.4 million (US$310.1 million) as of December 31, 2024.
• The auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The IPO aims to raise approximately US$21.4 million in net proceeds (or US$24.9 million if over-allotment option is fully exercised) at an assumed price of US$5.00 per ADS.
• The company plans to use the net proceeds for supply chain stocking (35%), departmental and geographic expansion (25%), working capital (20%), research and development (10%), and general corporate purposes (10%).
• The company operates under a dual-class voting structure, with Mr. Zhenyang Shi (Chairman and CEO) holding 76.0% of the aggregate voting power post-offering, making the company a controlled company under Nasdaq rules.

Sentiment

Score: 3

Explanation: The company exhibits strong operational growth metrics and market positioning in a growing industry. However, the persistent net losses, negative operating cash flows, worsening working capital deficit, and the auditor's 'going concern' opinion, coupled with significant reliance on related party loans, indicate substantial financial instability and high risk. The positive operational trends are overshadowed by severe financial challenges and uncertainties regarding long-term viability without significant capital infusion and a shift to profitability.

Positives

• The company is a leading online medical services platform for chronic diseases in China, ranking sixth in the Internet hospital market by contracted doctors.
• Cumulative contracted doctors stabilized at over 214,217 as of December 31, 2024, indicating a strong medical professional base.
• Transacting patients increased from 654,817 in 2023 to 699,338 in 2024, showing user growth.
• The 90-day patient repurchase rate increased from 63.7% in 2023 to 66.2% in 2024, indicating high patient loyalty and stickiness.
• Average revenue per paying patient increased from RMB714 in 2023 to RMB766 in 2024.
• Mature doctors retention rate remained high at 99.4% in 2024 (from 99.9% in 2023), suggesting strong doctor engagement.
• Net revenues grew by 12.4% from RMB304.9 million in 2023 to RMB342.6 million (US$46.9 million) in 2024.
• Gross profit margin improved from 12.7% in 2023 to 13.9% in 2024.
• Net cash used in operating activities significantly decreased from RMB45.8 million in 2023 to RMB16.1 million (US$2.2 million) in 2024, indicating improved operational efficiency.
• The company has a well-established pharmaceutical supply chain with 42,493 SKUs as of December 31, 2024, including 13,267 prescription drugs.
• The company has obtained online medical insurance payment qualification from Guangzhou Municipal Medical Security Bureau, with plans for broader implementation.
• The company has completed the required filings with the CSRC for this offering, and the CSRC has published the filing results on January 17, 2025.

Negatives

• The company has incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• The company has negative cash flows from operating activities in both 2023 (RMB45.8 million) and 2024 (RMB16.1 million).
• The company has a significant accumulated deficit of RMB2,263.4 million (US$310.1 million) as of December 31, 2024.
• The working capital deficit worsened from RMB112.6 million in 2023 to RMB141.6 million (US$19.4 million) in 2024.
• The auditor's report includes an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• The company has relied on related party loans with varying interest rates (0.00% to 20.00%) and has significant outstanding related party debt (RMB356.7 million non-current as of Dec 31, 2024).
• Sales and marketing expenses increased by 29.0% from RMB43.7 million in 2023 to RMB56.4 million (US$7.7 million) in 2024, representing a higher percentage of net revenues (16.5% in 2024 vs. 14.3% in 2023).
• Gross profit margin for Internet hospital services decreased from 50.1% in 2023 to 42.7% in 2024, mainly due to increased online pharmacy sales of lower-margin products.
• The company has not been in full compliance with PRC labor laws regarding social insurance and housing provident fund contributions, with unpaid amounts of RMB2.6 million for both 2023 and 2024.
• The company does not carry insurance covering medical malpractice claims and professional liability insurance for doctors on its platform.
• The company has a limited number of key suppliers, with one supplier accounting for 39.1% of total purchases in 2024, posing supply chain risk.
• The company has not distributed any earnings or settled amounts owed under VIE agreements to date, and has no plan to do so in the foreseeable future.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to net losses, negative operating cash flows, and significant working capital and accumulated deficits.
• Reliance on Variable Interest Entity (VIE) structure, which may not be as effective as direct ownership and faces uncertainties regarding interpretation and application of current and future PRC laws and regulations.
• Potential for severe penalties or forced relinquishment of interests in VIE operations if PRC government deems contractual arrangements non-compliant with foreign investment restrictions.
• Risk of VIE or its shareholders failing to perform obligations under contractual arrangements, requiring substantial costs and reliance on potentially insufficient legal remedies under PRC law.
• Potential conflicts of interest with VIE shareholders that could materially and adversely affect business and financial condition.
• Uncertainties with respect to the enforcement of laws and changes in laws and regulations in China, which could adversely affect operations and limit legal protections.
• PRC governmental authorities' significant oversight and discretion over business operations, potentially limiting or hindering ability to offer securities or causing value decline.
• Requirement for CSRC approval or filing for this offering and future capital raising activities, with potential sanctions for non-compliance or delays.
• Risks related to cybersecurity and data privacy, including potential for improper use or disclosure of large amounts of user data, and evolving PRC regulations (Cybersecurity Review Measures, Data Security Law, PIPL).
• Potential for medical liability claims in connection with online healthcare services, with no medical malpractice insurance coverage.
• Failure to properly manage doctors on the platform, including compliance with practicing licenses and multi-institution registration, leading to penalties or disputes.
• Stringent scrutiny and evolving regulations on the sale of prescription drugs in China, posing compliance challenges.
• Inability to develop existing information infrastructure and technologies or recoup investments, and failure to innovate or adapt to changing user requirements.
• Risk of undetected errors or improper operation in self-developed technologies, affecting business functionality and reputation.
• Failure to maintain optimal inventory levels, leading to increased operating costs or unfulfilled customer orders.
• Liability for content available in the ecosystem that is alleged to be factually incorrect, unlawful, or socially destabilizing.
• Dependence on a limited number of key suppliers, posing risks of delivery delays or inability to meet obligations.
• Lack of requisite approvals, licenses, or permits, or failure to maintain existing ones, leading to fines, penalties, or operational disruptions.
• Non-compliance with PRC labor laws and regulations, including social insurance and housing provident fund contributions, potentially leading to penalties and increased costs.
• Reliance on the continued efforts of senior management and key employees, with risks of disruption if they are unable or unwilling to continue.
• Inability to detect or prevent fraud or other misconduct committed by employees or third parties, leading to financial loss and reputational damage.
• Reliance on assumptions and estimates for key operating metrics, with inaccuracies potentially harming reputation and business.
• Need for additional capital, with no assurance of obtaining it on favorable terms or at all, leading to liquidity restrictions and potential dilution.
• Risk of trading prohibition under the Holding Foreign Companies Accountable Act (HFCAA) if PCAOB is unable to inspect auditor for two consecutive years in the future, leading to delisting.
• Dual-class voting structure limits public shareholders' ability to influence corporate matters and could discourage change of control transactions.
• Potential for short seller attacks to drive down market price.
• No expectation of paying cash dividends in the foreseeable future, requiring reliance on price appreciation for investment return.
• Immediate and substantial dilution for new investors due to initial public offering price being substantially higher than net tangible book value per share.
• Substantial future sales or perceived potential sales of ADSs in the public market could cause price decline.
• Anti-takeover provisions in memorandum and articles of association could limit shareholder influence.
• Limited voting rights for ADS holders compared to registered shareholders, and potential for discretionary proxy voting by depositary.
• Potential for not receiving cash dividends if depositary deems it impractical.
• Limitations on transfer of ADSs due to depositary's book closures or regulatory requirements.
• Dilution of holdings due to future equity issuance and inability to participate in rights offerings.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to incorporation under Cayman Islands law and PRC operational base.
• Unenforceability of certain judgments obtained against the company by shareholders.
• Waiver of jury trial for claims arising under the deposit agreement.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. investors.
• Uncertainty regarding the specific use of a portion of the net proceeds from the offering.

Future Outlook

The company plans to continue recruiting quality doctors and attracting more patient users, expand and strengthen its presence in key Chinese cities and provinces, enhance supply chain capabilities, and invest in research and development to improve technology. It also intends to explore new patient acquisition channels via B2B collaboration, utilize accumulated big data to empower the industry, and expand its chronic disease management experience to more medical areas. The company aims to improve business profitability and generate sufficient cash flow from operations, seeking additional working capital through debt and equity financings.

Management Comments

• Our mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses.
• Our vision is to become the most trustworthy medical and healthcare services platform.
• We believe that doctors are the most important resource in the medical services industry.
• We have established an open Internet hospital business model that focuses on serving doctors.
• Our platform only provides services for follow-up patients who already have prescriptions from separate, offline services.
• Our pharmacist verification system ensures that doctors' prescriptions comply with the relevant rules and regulations.
• We believe that our business will benefit from the state-promulgated policies to strengthen the prevention and treatment of chronic diseases, as well as the development of China's digital healthcare industry.
• We currently do not have cash management policies in place that dictate how funds are transferred between the Company, our Hong Kong subsidiary, our WFOE, the VIE, and the investors, including potential U.S. investors. Rather, the funds can be transferred in accordance with the applicable PRC laws and regulations.
• We have no plan to distribute earnings or settle amounts owed under the VIE agreements in the foreseeable future.

Industry Context

The company operates within China's rapidly expanding digital healthcare and chronic disease management (CDM) industries. The market is driven by factors such as an aging population, increasing prevalence of chronic diseases, growing health awareness (catalyzed by COVID-19), and unequal distribution of medical resources. Digitalization is transforming healthcare, with significant growth projected for the digital health and wellness market (CAGR of ~23.1% from 2022 to 2027). The industry is characterized by evolving technology, regulatory changes, and increasing doctor participation in online services. The company's focus on chronic disease management leverages the inelastic demand for frequent follow-up visits and drug purchases in this segment.

Comparison to Industry Standards

• PomDoctor ranked sixth among participants in the China Internet Hospital Market in 2022, based on the number of contracted doctors (212,000), indicating a notable position in the competitive landscape.
• The company's mature doctors retention rate of 99.4% in 2024 (99.9% in 2023) is described as 'top-level' within the industry, suggesting strong performance in retaining medical professionals.
• The 90-day patient repurchase rate of 66.2% in 2024 (63.7% in 2023) is highlighted as beneficial for chronic disease management, implying a competitive advantage in patient stickiness.
• The company's standing inventories of prescription drugs (6,000 to 7,000 SKUs) are significantly higher than a traditional public hospital (1,000 to 3,000 SKUs), indicating a broader product offering.
• The average inventory turnover days of top 5 offline pharmacies in China in 2022 were 87.8 days, compared with 26.3 days in the United States, highlighting a general industry inefficiency that digital solutions like PomDoctor's aim to address.
• The company mentions industry peers like Teladoc Health, Inc. as models for exploring B2B collaboration with insurance companies, suggesting an aspiration to align with successful international strategies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• Zhenyang Shi (CEO) provided loans of RMB129.5 million (2023) and RMB135.7 million (US$18.6 million) (2024) at 4.90% annual interest, due December 31, 2026.
• Aixiangbao, a wholly-owned entity by Zhenyang Shi, assumed RMB221.0 million advertising liability from Focus Media on behalf of the company, repayable in non-cash method after five years (due August 10, 2026), non-interest bearing.
• Li Xu (CFO) provided loans of RMB5.0 million (2023) and RMB1.5 million (US$0.2 million) (2024) with varying terms (some non-interest bearing, some at 8.88% annual interest, due October 18, 2025 or on demand).
• Aihua Peng (close relative of a shareholder's management) provided loans of RMB4.8 million (2023) and RMB4.0 million (US$0.6 million) (2024) at 20.00% annual interest, due on demand.
• Guoji Luo (management) provided interest-free loans of RMB2.0 million (2023) and RMB0.8 million (US$0.1 million) (2024), due December 31, 2024 or on demand.
• Dexiang Wei (management) provided interest-free loans of RMB810,045 (2023) and RMB339,450 (US$46,504) (2024), due December 31, 2024 or on demand.
• Yongan Zhong (management) provided a non-interest bearing loan of RMB5.0 million (2019), with RMB2,685 (US$368) outstanding as of December 31, 2024.
• Wanmei Shi (CEO's sister) provided loans with aggregate amount of RMB21,000 (US$2,887) as of December 31, 2024, due on demand and non-interest bearing.
• The company had drug sales to Guangzhou Zhiyao Cloud Technology Co., Ltd. (a company controlled by management) of RMB123,073 (2023) and RMB1.2 million (US$0.2 million) (2024).
• The company purchased drugs from Guangzhou Aopolikang Biotechnology Co., Ltd. (a company controlled by management) of RMB142,031 (2023) and RMB25,499 (US$3,493) (2024).
• Guangzhou Aopolikang Biotechnology Co., Ltd. provided consulting services of RMB431,346 in 2023.
• Several bank loans are guaranteed by Zhenyang Shi, Li Xu, Wanmei Shi, Guoji Luo, Dexiang Wei, Yongan Zhong, and other management team members, and/or mortgaged by Zhenyang Shi's real property.

Stakeholder Impact

• **Shareholders**: New investors will experience immediate and substantial dilution. The dual-class voting structure significantly limits the influence of Class A ordinary shareholders and ADSs holders on corporate matters. No cash dividends are expected in the foreseeable future. The going concern opinion and financial deficits pose a high risk of investment loss.
• **Employees**: The company's non-compliance with PRC labor laws regarding social insurance and housing provident fund contributions could lead to penalties and affect employee benefits. The company's ability to attract and retain qualified personnel is critical for future success.
• **Customers (Patients)**: The company aims to provide improved medical information technology, collaborative CDM systems, and convenient access to medical resources, especially for chronic disease patients. However, potential medical liability claims, issues with doctor management, or technology failures could negatively impact customer experience and trust.
• **Suppliers**: The company's reliance on a limited number of key suppliers creates concentration risk. The company aims to secure favorable terms from suppliers by leveraging its scale and providing market insights.
• **Creditors**: The company has significant outstanding loans from related parties and financial institutions. The going concern opinion raises concerns about the company's ability to meet its obligations as they become due.

Next Steps

• Allocate approximately 35% of net IPO proceeds for supply chain stocking.
• Allocate approximately 25% of net IPO proceeds for expansion of departmental and geographic coverage.
• Allocate approximately 20% of net IPO proceeds for working capital.
• Allocate approximately 10% of net IPO proceeds for research and development.
• Allocate the balance of net IPO proceeds for general corporate purposes.
• Continue to recruit quality doctors onto the platform and attract more patient users.
• Establish a professional regional promotion team for each medical department.
• Further enhance PomDoctor's brand awareness and ease of use.
• Establish a team of Pom Nurses to strengthen platform-patient relationships.
• Expand presence initially in the Pearl River Delta, then gradually to Guangdong Province and all of China.
• Implement connection with the social insurance settlement system and launch pilot trial operations for online medical insurance payment in Guangzhou, preparing for broader expansion.
• Continue to expand the number and categories of pharmaceutical products and supplier channels.
• Optimize drug storage, distribution, and management capabilities.
• Continuously update and optimize Pom Doctor APP and WeChat official account (performance improvements, functionality expansions).
• Further enhance artificial intelligence and big data analysis capabilities for case retrieval and assisted diagnosis.
• Explore new patient acquisition channels via enhanced B2B collaboration with insurance companies.
• Provide accumulated clinical data (anonymized) to pharmaceutical companies for clinical trials and R&D.
• Share experience and insight in building and operating Internet hospitals to accelerate healthcare digitalization.
• Provide big data to commercial insurance companies to improve customer identification and product pricing.
• Provide big data to governmental authorities for drug pricing for social insurance.
• Replicate business model to more medical areas and departments beyond hepatopathy.
• Implement measures to address identified material weaknesses in internal control over financial reporting, including hiring personnel, strengthening financial reporting, and improving system security.

Key Dates

Recommendation

Keywords

Online Medical Services, Chronic Disease Management, Digital Healthcare, Pharmaceutical Supply Chain, Internet Hospital, American Depositary Shares, IPO, China, VIE Structure, Healthcare Technology, Telemedicine, Prescription Drugs, Nasdaq